• This 5-year plan aims to address the domestic and international MDR-TB crisis by building on the success of the U.S. Government's TB strategies and the WHO END TB Strategy while advancing research on this critical issue.

    Learn More


At USAID, we focus our investments on strengthening national TB strategies and programs through bilateral programs in priority countries with high rates of TB, drug-resistant TB and HIV-associated TB.

Graphic of a man coughing - 10.4 million new cases of TB
Graphic of a pair of lungs. 1.7 million deaths from TB
Graphic of a microscope. 600,000 new drug-resistant TB cases
Graphic of two pills. 130,000 drug-resistant TB patients started care

The U.S. Agency for International Development (USAID) supports high-quality screening, diagnosis and treatment services for millions of people affected by TB and multidrug-resistant tuberculosis (MDR-TB). In Fiscal Year 2016, with investments of $242 million focused primarily in 23 countries with bilateral TB funds, the U.S. Government achieved the following results in collaboration with each country's National TB Programs:


Countries with bilateral programs


Countries received technical assistance


TB cases detected


Percent increase in case notifications


Individuals with DR-TB started on appropriate treatment


Xpert cartridges procured under concessional pricing (cumulative)


Countries utilized the Bedaquiline Donation Program


Health workers trained


Countries completed drug-resistance surveys (cumulative)


Countries completed/completing TB prevalence surveys (cumulative)


Research studies focused on new treatment regimens supported

USAID's investments contributed to an estimated 53 million lives saved from 2000-2016, including people co-infected with HIV/AIDS.


What We Do

USAID works with partner governments to:

  • Prevent TB transmission and renew efforts to find the missing TB cases
  • Strengthen the capacity of national TB programs
  • Build country capacity to use existing resources and to turn evidence into policy
  • Expand the development of new TB diagnostics, drugs and vaccines

Last updated: December 06, 2017

Share This Page